Tofacitinib versus standard of care treatment in patients with COVID-19 pneumonia and respiratory failure: a multicenter cohort study
L. Akulkina (Moscow, Russian Federation), M. Brovko (Moscow, Russian Federation), N. Bulanov (Moscow, Russian Federation), P. Novikov (Moscow, Russian Federation), A. Zykova (Moscow, Russian Federation), V. Sholomova (Moscow, Russian Federation), A. Moiseev (Moscow, Russian Federation), A. Schepalina (Moscow, Russian Federation), A. Kitbalian (Moscow, Russian Federation), N. Chichkova (Moscow, Russian Federation), V. Fomin (Moscow, Russian Federation), S. Avdeev (Moscow, Russian Federation), N. Trushenko (Moscow, Russian Federation), S. Moiseev (Moscow, Russian Federation)
Source: Virtual Congress 2021 – Acute COVID - 19
Session: Acute COVID - 19
Session type: Oral Presentation
Number: 3970
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Akulkina (Moscow, Russian Federation), M. Brovko (Moscow, Russian Federation), N. Bulanov (Moscow, Russian Federation), P. Novikov (Moscow, Russian Federation), A. Zykova (Moscow, Russian Federation), V. Sholomova (Moscow, Russian Federation), A. Moiseev (Moscow, Russian Federation), A. Schepalina (Moscow, Russian Federation), A. Kitbalian (Moscow, Russian Federation), N. Chichkova (Moscow, Russian Federation), V. Fomin (Moscow, Russian Federation), S. Avdeev (Moscow, Russian Federation), N. Trushenko (Moscow, Russian Federation), S. Moiseev (Moscow, Russian Federation). Tofacitinib versus standard of care treatment in patients with COVID-19 pneumonia and respiratory failure: a multicenter cohort study. 3970
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: